Christopher T. Cox

Christopher T. Cox: Attorney with Cadwalader, Wickersham & Taft LLP


Christopher T. Cox represents clients in a wide array of corporate and financial matters, with extensive experience in mergers and acquisitions and corporate governance. Previously Chair of Cadwalader's Corporate Group and a member of the Firm's Management Committee, Chris has represented public and private acquirors, targets, investment banks and private equity sponsors in connection with negotiated and contested mergers and acquisitions, restructurings, spin-offs, joint ventures, proxy contests and IP monetizations and other complex financings. He also represents foreign and domestic entities in cross-border business transactions.

In addition to his transactional experience, Chris counsels clients on a broad range of corporate, securities and business-related matters and on matters of corporate policy and strategy, including directors' duties and responsibilities, governance, disclosure issues and compliance. With a premier reputation for advising businesses in the life sciences industry, Chris was selected by The American Lawyer as one of its Dealmakers of the Year for his work with Irish drugmaker elan Corporation, as well as 2014 Global M&A Deal of the Year: Europe/Ireland award for his representation of elan in its sale to Perrigo Company. He was named an M&A Atlas Top 50 Global M&A Lawyers for 2014 Distinction in Dealmaking, and won the Deal of the Year award for elan/Perrigo in 2014 and U.S.A. M&A Deal of the year - Large Markets for Acorda/Civitas. Chris is recognized for his work in mergers, acquisitions and buyouts by Chambers and The Legal 500 and he was among the first 100 lawyers named to the 2015-2016 Lawdragon 500 annual guide. His work for Credit Suisse on behalf of Zealand Pharma was nominated for Scrips Financing Deal of the Year Award and he was shortlisted for the IFLR European M&A Deal of the Year award.

Chris's transactional experience covers a broad range of industries, including communications, defense and aerospace, energy, financial institutions, insurance, life sciences, media, natural resources, real estate, retail and technology.

Chris received his B.S. from the University of Missouri and his J.D. from the University's Law School, where he was a member of the Missouri Law Review. He is admitted to practice in the State of New York.


•Salix Pharmaceuticals, Ltd. in its $15.6 billion acquisition by Valeant Pharmaceuticals International, Inc.
•Canadian Pension Plan Investment Board in its $12 billion acquisition of Antares Capital, a part of the General Electric financial services arm GE Capital.
•Pershing Square Capital Management in its acquisition of a 7.5% stake in Mondelez International, Inc.
•Cigna Corporation in connection with the public offering of $900 million of 3.250% Senior Notes due 2025.
•Cigna Corporation in connection with its acquisition of QualCare Alliance Networks, Inc.
•JP Morgan Chase as financial advisor in connection with Pfizer's $17 billion acquisition of Hospira, Inc.
•Acorda Therapeutics, Inc. in its acquisition of Civitas Therapeutics, Inc.
•Forbes Media LLC in its sale of a majority equity interest to a group of international investors led by Integrated Asset Management (Asia) Limited.
•Salix Pharmaceuticals in its terminated combination with Cosmo Technologies, a subsidiary of Cosmo Pharmaceuticals.
•elan Corporation in its $8.6 billion acquisition by Perrigo Company.
•elan Corporation in its successful defense of a hostile tender offer by Royalty Pharma.
•Air Products and Chemicals in its agreement with Pershing Square Capital Management following the 9.8% investment position taken by Bill Ackman.
•Cigna Corporation in connection with a $1.5 billion Revolving Credit and Letter of Credit Agreement.
•Credit Suisse as sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. in the monetization of the expected royalty stream from the sales of Salviso in the European Union by its commercial partner Grunenthal GmbH.
•Credit Suisse, as sole structuring advisor and sole placement agent, in connection with a structured bond financing by Zealand Pharma A/S secured by lixisenatide (Lyxumia) royalties.
•Centerview Partners LLC, as financial advisor to Avanir Pharmaceuticals, Inc., in connection with the sale of Avanir to Otsuka Pharmaceuticals Co., Ltd.
•Brandon Point Industries Limited and Woodford Investment Management in connection with an equity investment in Viamet Pharmaceuticals Holdings, LLC.
•Cadiz Inc. in connection with a public equity offering.
•Dell Inc.'s financial advisor in connection with Dell's $24.9 billion acquisition by Michael Dell and Silver Lake Partners.
•elan Corporation in its attempted $1.0 billion acquisition from Theravance, Inc. of a 21% participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc.
•HealthCare Royalty Partners in connection with a debt financing to Dyax Corp. secured by Dyax's phage display Licensing and Funded Research Program.
•elan Corporation in connection with a $1 billion share repurchase.
•Elan Corporation in connection with a Rule 144A offering of $850 million in aggregate principal amount of senior notes.
•Par Pharmaceutical's financial advisor in connection with Par's $1.8 billion acquisition by TPG Capital.
•elan Corporation in the $3.25 billion sale of its interest in Tysabri to Biogen Idec.
•Cadiz Inc. in connection with a comprehensive debt refinancing.
•HealthCare Royalty Partners in connection with a royalty financing to Vertex Pharmaceuticals.
•elan Corporation in connection with the spinoff of its drug discovery business into a new, independent publicly-traded company, Prothena Corporation.
•YMF Media in its acquisition of the intellectual property rights of Kiss FM from Emmis Communications.
•Deutsche Bank, BNP PARIBAS and Banca IMI, as joint book-running managers, in connection with the public offering of 300 million in aggregate principal amount of Senior Notes by Air Products and Chemicals.
•Nektar Therapeutics in its sale of royalties on future sales of CIMZIA and Mircera to Royalty Pharma.
•HealthCare Royalty Partners in connection with a royalty financing with, and equity investment in, Zogenix, Inc.
•Corning Incorporated's financial advisor in connection with Corning's $730 million purchase of Becton Dickinson's Discovery Labware unit.
•HealthCare Royalty Partners in connection with its Synthetic Royalty investment in AcuFocus, Inc.
•Forbes in its sale of a minority stake in Forbes Media, which includes Forbes magazine, the Web site and a number of smaller media properties, to Elevation Partners.
•White Birch Paper Company in its acquisition of SP Newsprint Company.
•elan Corporation in connection with the $960 million sale of its drug technology unit, EDT, to Alkermes plc and in connection with elan's secondary offering of 25% of the outstanding ordinary shares of Alkermes plc.
•elan Corporation in connection with the $1.4 billion sale of its Alzheimer's Immunotherapy Program to an affiliate of Johnson &Johnson, honored as the Biotech M&A/Alliance Deal of the Year, 2010.
•elan Corporation in connection with its settlement of the U.S. Department of Justice's investigation of sales and marketing practices for Zonegran (zonisamide).
•ICON plc in its acquisition of Prevalere Life Sciences, Inc.
•ICON plc in its acquisition of Healthcare Discoveries, Inc., formerly a wholly-owned subsidiary of Catalyst Pharma Group Inc.
•Beazer Homes in connection with investigations by, and settlement with, the Securities and Exchange Commission, the Department of Justice and other authorities concerning accounting irregularities and mortgage practices.
• in its acquisition of Fannie May Confections Brands, Inc.
•ORS Nasco in its sale to Brazos Private Equity Partners, LLC.
•Mediacom Communications Corporation's financial advisors in connection with Mediacom's $2.1 billion acquisition of AT&T Broadband Cable Systems.
•JPMorgan in connection with the initial public offering of Mediacom Communications Corporation.
•ICON plc in a public offering of American Depositary Shares.

News & Resources


News Releases

•Cadwalader Achieves Delaware Supreme Court Victory in Merger Challenge

Jan 26, 2017

Recent Press

•Tax thread runs through pharma deals

Apr 07, 2014


•Cadwalader's Christopher Cox Recognized As Top 100 Leading Lawyer in 2016 Lawdragon 500

Feb 23, 2016


Clients & Friends Memos

Glass Lewis Opens Registration for Issuer Data Report Requests, including expanding access to certain companies in Canada and Europe

Jan 08, 2016


Second Annual SDX Symposium

Nov 16, 2015


Mar 26, 2014


Cadwalader is a Leading Advisor to Corporations and Financial Institutions

Sep 18, 2013

Areas of Practice (6)

  • Corporate
  • Corporate Finance
  • Corporate Governance
  • Distressed Investing and Mergers & Acquisitions
  • Mergers & Acquisitions
  • Private Equity

Education & Credentials

Contact Information:
212 504 6888  Phone
212 504 6666  Fax
University Attended:
University of Missouri, B.S., 1987
Law School Attended:
University of Missouri, School of Law, J.D., 1992
Year of First admission:
1993, New York
Inversions: The View from Ireland

Jul 07, 2014

M&A Update: Senator Levin Introduces Anti-Inversion Act

May 21, 2014

M&A Update: New Rules Will Limit Shareholders' Tax-Free Treatment on Inversions

Apr 25, 2014

M&A Update: Treasury Department Proposes To Expand Anti-Inversion Rules

Mar 11, 2014


The American Lawyer: Dealmakers 2014 When Blarney Fails featuring Christopher Cox

Apr 02, 2014



Quorum: March 2014


Peer Reviews

This lawyer does not have peer reviews.

*Peer Reviews provided before April 15, 2008 are not displayed.

Client Reviews

This attorney does not have client reviews.

Documents ({{amountArticles}})

Documents by this lawyer on
Other documents: ,

New York, New York

Contact Christopher T. Cox

Please correct the fields highlighted in red.

By clicking on the "Submit" button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Martindale and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.

You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The Internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.